Premium
Desipramine Treatment for Cocaine Dependence in Buprenorphine‐ or Methadone‐treated Patients: Baseline Urine Results as Predictor of Response
Author(s) -
Kosten Thomas,
Sofuoglu Mehmet,
Poling James,
Gonsai Kishor,
Oliveto Alison
Publication year - 2005
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1080/10550490590899817
Subject(s) - buprenorphine , methadone , desipramine , placebo , urine , cocaine dependence , medicine , anesthesia , randomized controlled trial , opioid , addiction , psychiatry , antidepressant , receptor , alternative medicine , pathology , hippocampus
The prognostic importance of baseline urines for cocaine was examined in a randomized, placebo‐controlled, twelve‐week clinical trial in 165 opioid‐and cocaine‐dependent patients who were treated with desipramine (DMI) in combination with buprenorphine (BUP) or methadone (Meth). Patients with a cocaine‐positive urine at baseline (CU+) had significantly fewer cocaine‐free urines than those with a negative urine at baseline (CU‐neg). The CU+ patients showed no treatment effects of DMI compared to placebo, but the CU‐neg patients showed a treatment effect of DMI. This DMI effect was significant in patients maintained on BUP but not on Meth.